Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 10,000
- 试验地点
- 16
- 主要终点
- Major adverse cardiovascular events (MACE)
研究概览
简要总结
This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.
排除标准
- •Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
- •Patient request to withdraw from the study.
研究组 & 干预措施
Patients undergoing hematopoietic stem cell transplantation
Patients who undergo allogeneic hematopoietic stem cell transplantation at participating medical center.
结局指标
主要结局
Major adverse cardiovascular events (MACE)
时间窗: At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.
Major adverse cardiovascular events (MACE) after hematopoietic stem cell transplantation.
次要结局
- Cardiovascular events(At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.)
- Overall survival(At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.)
- Event-free survival(At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.)
- Complications of hematopoietic stem cell transplantation(At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.)
研究者
Xiao Hui Zhang
MD
Peking University People's Hospital